Follow-up of Migraine Patients on Eptinezumab (EPTI-CO)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Migraine

Treatments: Other: None, pure observationnal study

Study type: Observational

Funder types: Other

Identifiers

NCT06446804

LOCAL/2024/AL-01

Details and patient eligibility

About

The October 2022 Transparency Commission considers that VYEPTI (eptinezumab) is a treatment option for patients suffering from severe migraine with at least 8 migraine days per month, who have failed at least two prophylactic treatments and have no cardiovascular impairment.

Since the beginning of 2023, eptinezumab has been available in France as an inpatient treatment prescribed by a migraine neurologist in a growing number of centres. The Saint-Denis Hospital and the Nîmes University Hospital are among the first centres to have started. The investigators from these 2 centres have therefore decided to pool their data to provide the first French feedback on its effectiveness.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients suffering from severe migraine with at least 8 migraine days per month

  • Patients who have failed at least 2 disease-modifying treatments,
  • Patients treated with quarterly infusions of eptinezumab since March 2023 in a day hospital at Saint-Denis Hospital and Nîmes University Hospital.

Exclusion criteria

• Patient refusing to participate

Trial design

60 participants in 1 patient group

Migraine patients

Description:

Patients with severe migraine, with at least 8 migraine days per month and at least 2 failed background treatments.

Treatment:

Other: None, pure observationnal study